Development of Patient-Derived Tumor Xenograft Models.

Methods Mol Biol 2019 ;1862:217-225

Gynecological Oncology, Oncology Department, LKI Leuven Cancer Institute KU Leuven-University of Leuven, Leuven, Belgium.

In spite of the latest advancements in understanding cancer development and progression, drugs successful in preclinical testing often fail upon reaching phase III clinical trials. A reason for this is the use of inappropriate preclinical models that do not preserve tumor heterogeneity. Although used for decades, cell cultures derived from patients substantially deviate from their original biopsy upon culturing; moreover, they cannot predict the response of an organism as a whole.Patient-derived xenograft (PDX) models are emerging as powerful tools since they have a predictive therapeutic value and preserve the heterogeneity of the original tumors. PDX are established by implanting freshly isolated tumors from patients into immunocompromised mice, allowing for the progressive growth and amplification of cancer tissue for in vivo testing. Here, we describe the detailed methods we developed to establish PDX from both surgically removed endometrial cancer fragments (endometrial cancer) and fine-needle aspiration biopsies (pancreatic cancer).

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8769-6_15DOI Listing
June 2019
9 Reads

Publication Analysis

Top Keywords

endometrial cancer
8
cancer
5
therapeutic preserve
4
preserve heterogeneity
4
tools predictive
4
powerful tools
4
predictive therapeutic
4
heterogeneity original
4
implanting freshly
4
freshly isolated
4
established implanting
4
pdx established
4
original tumors
4
tumors pdx
4
emerging powerful
4
models emerging
4
deviate original
4
original biopsy
4
patients deviate
4
derived patients
4

Similar Publications